

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1-10 (Cancelled)

11 (Currently Amended). A method for treating an individual suffering from multiple sclerosis (MS) comprising ~~administering~~ administering to said individual an A3 adenosine receptor agonist (A3RAg).


12. (Currently Amended) The method of Claim 11, wherein said A3RAg is orally administered.

13 (Currently Amended). The method of Claim 11, wherein said A3RAg is a compound within the scope of the general formula (I):




wherein,

- **R₁** represents an alkyl, hydroxyalkyl, carboxyalkyl or cyanoalkyl or a group of the following general formula (II):



in which:

- **Y** represents an oxygen, sulfur or CH₂;
- **X₁** represents H, alkyl, R^aR^bNC(=O)- or HOR^c-, wherein
 - **R^a** and **R^b** may be the same or different and are ~~selected from the group consisting of hydrogen,~~
alkyl, amino, haloalkyl, aminoalkyl, BOC-aminoalkyl,
~~and or~~ cycloalkyl or are joined together to form a
heterocyclic ring containing two to five carbon
atoms; and
 - **R^c** is ~~selected from the group consisting of~~ alkyl,
amino, haloalkyl, aminoalkyl, BOC-aminoalkyl, ~~and or~~
cycloalkyl;
- **X₂** is H, hydroxyl, alkylamino, alkylamido or
hydroxyalkyl;
- **X₃** and **X₄** represent independently hydrogen, hydroxyl,
amino, amido, azido, halo, alkyl, alkoxy, carboxy,
nitrilo, nitro, trifluoro, aryl, alkaryl, thio,
thioester, thioether, -OCOPh, or -OC(=S)OPh or both **X₃** and
X₄ are oxygens connected to >C=S to form a 5-membered
ring, or **X₂** and **X₃** form the ring of formula (III):



where **R'** and **R''** represent independently an alkyl group;


- **R₂** is ~~selected from the group consisting of~~ hydrogen, halo, alkylether, amino, hydrazido, alkylamino, alkoxy, thioalkoxy, pyridylthio, ~~alkenyl, alkenyl, alkynyl, thio, and or~~ alkylthio; and

- **R₃** is a group of the formula -NR₄R₅, wherein

- **R₄** is a hydrogen atom or ~~a group selected from~~ alkyl, substituted alkyl or aryl-NH-C(Z)-, with **Z** being O, S, or NR^a with **R^a** having the above meanings;


~~wherein with the proviso that~~ when **R₄** is hydrogen then

- **R₅** is ~~selected from the group consisting of an R- and or~~ S-1-phenylethyl, benzyl, phenylethyl or anilide ~~groups group,~~ unsubstituted or substituted in one or more positions with a substituent that is ~~selected from the group consisting of~~ alkyl, amino, halo, haloalkyl, nitro, hydroxyl, acetoamido, alkoxy, ~~and or~~ sulfonic acid or a salt thereof; benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β-alanylaminobenzyl, T-BOC-β-alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or cycloalkyl; or **R₅** is a group of the following formula:



~~or~~ and with the further proviso that when **R₄** is an alkyl or aryl-NH-C(Z)-, then, **R₅** is ~~selected from the group consisting of~~ heteroaryl-NR^a-C(Z)-, heteroaryl-C(Z)-, alkaryl-NR^a-C(Z)-, alkaryl-C(Z)-, aryl-NR-C(Z)- ~~and or~~ aryl-C(Z)-, **Z** representing an oxygen, ~~sulfer~~ sulfur or amine;
or a physiologically acceptable salt of the above compound.

14 (Currently Amended). The method of claim 11, wherein said A3RAg is a nucleoside derivative of the general formula (IV):



wherein,


- **X₁** represents H, alkyl, R^aR^bNC(=O)- or HOR^c-, wherein

- R^a and R^b may be the same or different and are ~~selected from the group consisting of~~ hydrogen, alkyl, amino, haloalkyl, aminoalkyl, BOC-aminoalkyl, ~~and or~~ cycloalkyl or are joined together to form a heterocyclic ring containing two to five carbon atoms; and

- R^c is ~~selected from the group consisting of~~ alkyl, amino, haloalkyl, aminoalkyl, BOC-aminoalkyl, ~~and or~~ cycloalkyl;

- R_2 is ~~selected from the group consisting of~~ hydrogen, halo, alkylether, amino, hydrazido, alkylamino, alkoxy, thioalkoxy, pyridylthio, ~~alkenyl;~~ alkenyl, alkynyl, thio, ~~and or~~ alkylthio; and

- R_5 is ~~selected from the group consisting of an R- and or~~ S-1-phenylethyl, benzyl, phenylethyl or anilide ~~groups~~ group, unsubstituted or substituted in one or more positions with a substituent that is ~~selected from the group consisting of~~ alkyl, amino, halo, haloalkyl, nitro, hydroxyl, acetoamido, alkoxy, ~~and or~~ sulfonic acid or a salt thereof; benzodioxanemethyl, fururyl, L-propylalanylaminobenzyl, β -alanylaminobenzyl, T-BOC- β -alanylaminobenzyl, phenylamino, carbamoyl, phenoxy or cycloalkyl; or R_5 is a group of the following formula:



and physiologically acceptable salts of said nucleoside derivative.

15 (Currently Amended). The method of Claim 11, wherein said A3RAg is ~~selected from~~ N⁶-2- (4-aminophenyl)ethyladenosine (APNEA), N⁶-(4-amino-3-iodobenzyl)adenosine- 5'-(N-methyluronamide) (AB-MECA), N⁶-(3-iodobenzyl)-adenosine-5'-N- methyluronamide (IB-MECA) ~~and, or~~ 2-chloro-N⁶-(3-iodobenzyl)- adenosine-5'-N-methyluronamide (Cl-IB-MECA).